In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

King Pharmaceuticals, Inc.

http://www.kingpharm.com

Latest From King Pharmaceuticals, Inc.

Cosentyx Becomes First Biologic Approved For HS In Nearly A Decade

The Swiss major should have a considerable first-to-market advantage over other IL-17 biologics from the likes of UCB and Acelyrin that are also targeting the hidradenitis suppurativa space.

Immune Disorders Approvals

Novartis Committed To Carving Out More Indications For Cosentyx

The Swiss behemoth’s chief commercial officer Marie-France Tschudin tells Scrip that the firm will keep expanding Cosentyx into disease areas “that have been a little bit neglected.”

Immune Disorders Business Strategies

Acelyrin Enters The Spotlight As NASDAQ Debut Dawns

The US biotech intends to use the proceeds from its upcoming IPO to advance lead candidate izokibep, an interleukin-17A inhibitor that is showing potential as a treatment for hidradenitis suppurativa.

Financing Immune Disorders

Financing Quarterly Statistics, Q4 2022

During Q4, biopharmas brought in an aggregate $17.5bn in financing and device company fundraising totaled $1.9bn; while in vitro diagnostic firms and research tools players raised $848m.

Deals BioPharmaceutical
See All

Company Information

  • Industry
  • Medical Devices
  • Pharmaceuticals
    • Specialty Pharmaceuticals
  • Other Names / Subsidiaries
    • Alpharma Inc.
UsernamePublicRestriction

Register